Theratechnologies Receives Final Court Approval for Acquisition by Future Pak
PorAinvest
martes, 16 de septiembre de 2025, 5:11 pm ET1 min de lectura
THTX--
Theratechnologies, a specialty biopharmaceutical company focused on innovative therapies, has received strong support from its shareholders for the proposed acquisition. The arrangement resolution was approved by an overwhelming majority, demonstrating confidence in the proposed transaction. The company's senior vice president and chief financial officer, Philippe Dubuc, stated, "We are pleased with the support from our shareholders and look forward to completing this transaction, which will enhance our ability to deliver patient-centric solutions."
Future Pak, a privately held contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products, will acquire Theratechnologies. Future Pak operates across retail, specialty, and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions. The acquisition will allow Future Pak to expand its product offerings and strengthen its position in the biopharmaceutical market.
The proposed arrangement remains subject to certain customary closing conditions, including the issuance of a final order by the Superior Court of Québec following the hearing expected to take place on September 16, 2025. The company has stated that the expected date for the receipt of the final order is September 25, 2025, subject to the satisfaction of remaining closing conditions [1].
For further information, please contact:
- Theratechnologies Inc.
- Investor inquiries: Philippe Dubuc, Senior Vice President and Chief Financial Officer, pdubuc@theratech.com, 438-315-6608
- Media inquiries: Julie Schneiderman, Senior Director, Communications & Corporate Affairs, communications@theratech.com, 514-336-7800
- Future Pak: media@futurepak.com
Theratechnologies has received final court approval for its plan of arrangement to be acquired by Future Pak. The acquisition is expected to be completed on or about September 25, 2025, subject to the satisfaction of remaining closing conditions. The company's shareholders approved the arrangement at a special meeting held on September 12, 2025.
Montreal, Sept. 12, 2025 — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) has announced that its shareholders have approved the company's plan of arrangement to be acquired by Future Pak, LLC. The acquisition, which was approved by 97.44% of the votes cast, is subject to customary closing conditions, including final court approval. The acquisition is expected to be completed on or about September 25, 2025 [1].Theratechnologies, a specialty biopharmaceutical company focused on innovative therapies, has received strong support from its shareholders for the proposed acquisition. The arrangement resolution was approved by an overwhelming majority, demonstrating confidence in the proposed transaction. The company's senior vice president and chief financial officer, Philippe Dubuc, stated, "We are pleased with the support from our shareholders and look forward to completing this transaction, which will enhance our ability to deliver patient-centric solutions."
Future Pak, a privately held contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products, will acquire Theratechnologies. Future Pak operates across retail, specialty, and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions. The acquisition will allow Future Pak to expand its product offerings and strengthen its position in the biopharmaceutical market.
The proposed arrangement remains subject to certain customary closing conditions, including the issuance of a final order by the Superior Court of Québec following the hearing expected to take place on September 16, 2025. The company has stated that the expected date for the receipt of the final order is September 25, 2025, subject to the satisfaction of remaining closing conditions [1].
For further information, please contact:
- Theratechnologies Inc.
- Investor inquiries: Philippe Dubuc, Senior Vice President and Chief Financial Officer, pdubuc@theratech.com, 438-315-6608
- Media inquiries: Julie Schneiderman, Senior Director, Communications & Corporate Affairs, communications@theratech.com, 514-336-7800
- Future Pak: media@futurepak.com

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios